These data support the hypothesis that the combination of cetuximab with PI3K/Akt pathway inhibition might be a promising novel therapeutic strategy to overcome acquired cetuximab resistance in HNSCC patients. This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.